使用Player FM应用程序离线!
Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer
Manage episode 450415478 series 1021077
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.”
At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.
184集单集
Manage episode 450415478 series 1021077
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.”
At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.
184集单集
כל הפרקים
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。